This HTML5 document contains 70 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00562/identifier/pharmgkb/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/drugbank/company/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00562/identifier/kegg-compound/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00562/identifier/pubchem-compound/
n17http://linked.opendata.cz/resource/drugbank/mixture/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00562/identifier/kegg-drug/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00562/identifier/pubchem-substance/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00562/identifier/drugbank/
n7http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n18http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00562/identifier/chemspider/
n4http://linked.opendata.cz/resource/drugbank/property/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00562/identifier/chebi/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB00562
rdf:type
n3:Drug
n3:description
Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue.
n3:group
approved
n3:indication
For the treatment of high blood pressure and management of edema.
n3:manufacturer
n8:271B47F4-363D-11E5-9242-09173F13E4C5 n8:271B47F5-363D-11E5-9242-09173F13E4C5 n8:271B47F6-363D-11E5-9242-09173F13E4C5 n8:271B47F7-363D-11E5-9242-09173F13E4C5
owl:sameAs
n7:DB00562 n18:DB00562
dcterms:title
Benzthiazide
adms:identifier
n10:3047 n11:2253 n12:2343 n13:46506752 n14:D00651 n15:DB00562 n16:C07759 n19:PA164776841
n3:mechanismOfAction
As a diuretic, benzthiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like benzthiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of benzthiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle.
n3:synonym
Benzthiazid 3-((Benzylthio)methyl)-6-chloro-7-sulfamoyl-2H-benzo-1,2,4-thiadiazine 1,1-dioxide Benzthiazide 3-Benzylthiomethyl-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide Benzothiazide Benztiazide 6-chloro-1,1-dioxo-3-(Phenylmethylsulfanylmethyl)-4H-benzo[e][1,2,4]thiadiazine-7-sulfonamide Benzotiazida 3-Benzylthiomethyl-6-chloro-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide Benzthiazidum 6-chloro-7-Sulfamoyl-3-benzylthiomethyl-2H-1,2,4-benzothiadiazine 1,1-dioxide
n3:toxicity
Symptoms of overdose include nausea, vomiting, fatigue, urinary problems and drowsiness.
n3:mixture
n17:271B47F3-363D-11E5-9242-09173F13E4C5 n17:271B47F2-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
30%
n3:synthesisReference
Samuel M. Fainberg, Porfirio F. Perez, "Stable solution of benzthiazide (3-[benzythiol methyl]-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide) suitable for parenteral administration and process of preparation." U.S. Patent US4022894, issued May 10, 1977.
n3:IUPAC-Name
n4:271B47FC-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4802-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4801-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B47FE-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B47FF-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4800-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4812-363D-11E5-9242-09173F13E4C5 n4:271B47FA-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4814-363D-11E5-9242-09173F13E4C5 n4:271B47FB-363D-11E5-9242-09173F13E4C5 n4:271B47F8-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B47F9-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B4815-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4808-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4809-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4803-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4804-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4806-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4805-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4807-363D-11E5-9242-09173F13E4C5
n3:absorption
Absorbed in the digestive tract.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
91-33-8
n3:category
n3:Bioavailability
n4:271B480E-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4810-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4811-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4813-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B480D-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B480C-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B480F-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B47FD-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B480A-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B480B-363D-11E5-9242-09173F13E4C5